Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2024-11-17
2025-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
50 female adult subjects will be enrolled in the study, recruited according to inclusion and non-inclusion criteria listed above. At least 40 subjects should complete the study in this 10-week study (wash-out phase for 2-week and treatment phase for 8 weeks). Subjects will need to refrain from using any product other than the provided products on face during the study phase.
1. Clinical Assessment (N=40 at least):
\*Clinical scoring for smoothness (visual), elasticity, cheek plumpness, radiance, global fine lines, firmness, dry lines, small folds on nasolabial zone (Atlas), underneath eye wrinkles (Atlas), forehead wrinkles (Atlas), nasolabial fold (Atlas), cheek folds: (Atlas), wrinkles of the corner of the lips (Atlas), inter-ocular wrinkles (Atlas), crow's feet wrinkles (Atlas), glabellar wrinkles (Atlas), horizontal neck fold (Atlas) by Dermatologist at T-2W, T0, Timm, T2W, T4W, T8W.
* Clinical scoring for eye bag (Atlas), intensity and coverage of dark circle (vascular) (0\~4 scale) by Dermatologist at T-2W, T0, T2W, T4W, T8W.
2. Image Capture and Analysis (N=40 at least):
\*The facial photo will be captured by VISIA CRP (Canfield, Gen 5.0) on left, front and right sides with Standard, Cross-polarized, Parallel-Polarized, Primos operated by trained technician at T0, Timm, T2W, T4W, T8W.
-Demo with mark line for forehead wrinkles, underneath eye wrinkles, crow's feet wrinkles
* Primos demo for crow's feet wrinkles
Image Analysis by Primos 5.8E:
-Wrinkle volume (mm³), Wrinkle area (mm²), total length (mm), count of crow's feet wrinkles
\*The facial photo will be captured by COLORFACE® (Newtone Technologies) on front side with closed eyes under Cross-Polarized mode at T0, T2W, T4W, T8W.
* Demo with dark circles.
Image Analysis by Image-Pro Plus 7.0:
* L\*, a\*, b\* and ITA° focus on underneath eye zone.
\*The local 3D photo will be captured by Primos-lite (Canfield) on both sides of underneath eye zone for eye bags by trained technician at T0, T2W, T4W, T8W. (at least 10 subjects with eye bags (Altas, 0\~6 scale) grade≥2)
* Demo with eye bags.
Image Analysis by Primos 5.8E:
-Rising Volume (mm³) of eye bags
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cream Short-term Efficacy Clinical Study
NCT07067086
ANTI-DYNAMIC LINE Test for Cream
NCT07067073
Anti-Wrinkle Efficacy Study of an Eye-Cream
NCT05805735
Serum Instant Anti-Redness Efficacy Clinical Study
NCT07058701
In-use Tolerance and Efficacy Study Under Dermatological and Ophthalmological Controls - Face Cream, RV4983A - LA3365
NCT07208227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Eye Cream Arm
Participants will apply the test eye cream (Formula# 899675 44A) twice daily on full face and neck for 8 weeks. The study is designed to evaluate improvements in facial wrinkles, eye bags, dark circles, skin firmness, elasticity, radiance, and smoothness in healthy Chinese women aged 20-50.
Test Eye Cream (Formula# 899675 44A)
A white cream formulated as eye cream (Formula# 899675 44A) provided by L'Oréal R\&I China. Participants will apply 1ml of the product on the full face and neck twice daily for 8 weeks. The aim is to evaluate its efficacy on facial wrinkles, eye bags, dark circles, and other skin aging signs in healthy Chinese women.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test Eye Cream (Formula# 899675 44A)
A white cream formulated as eye cream (Formula# 899675 44A) provided by L'Oréal R\&I China. Participants will apply 1ml of the product on the full face and neck twice daily for 8 weeks. The aim is to evaluate its efficacy on facial wrinkles, eye bags, dark circles, and other skin aging signs in healthy Chinese women.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Chinese women aged from 20-50 years old (must have subjects aged from 20-30 y.o.).
2. All skin types, with about 50% sensitive skin (self-declared).
3. Regular users of cleanser, anti-aging cream and sunscreen products.
4. Self-claim with wrinkles concern, also with lack of elasticity, firmness and plumpness.
5. Clinical grading by dermatologist on global face following:
Skin firmness (0-9 scale, 3≤ grade≤ 6) Skin elasticity (0-9 scale, 3≤ grade≤ 6) Skin radiance (0-9 scale, 3≤ grade≤ 6) Skin smoothness (0-9 scale, 3≤ grade≤ 6) Skin plumpness (0-9 scale, 3≤ grade≤ 6)
6. Clinical grading by dermatologist on face following:
Underneath eye wrinkles (Atlas Page 44\~45, 2≤ grade≤ 5) Forehead wrinkles (Atlas Page 30\~31, 1\<grade≤ 4) Nasolabial folds (Atlas Page 52\~53, 1\<grade) Crow's feet wrinkle (Atlas Page 36\~37, 1\<grade) Inter ocular wrinkles (Atlas Page 38\~39, 1\<grade) Wrinkles of the corner of the lips (Atlas Page 60\~61, 1\<grade) Dark circle (vascular) (0-4 scale, 2≤ grade) Eye bags (Atlas Page 42-43, 2≤ grade) (at least N=10)
7. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
8. In general good health at the time of the study.
9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
10. Must be willing to comply with all study protocol requirements (pay attention to: only use the provided product during the study, not take topical or oral treatment like retinol, hormone, anti-oxidant health-care products which may impact the efficacy of study).
Exclusion Criteria
2.Subject deprived of rights by a court or administrative order. 3.Major subject to a guardianship order. 4.Subject residing in a health or social care establishment. 5.Patient in an emergency setting. 6.Subject with a skin disease in the test areas (particularly e.g, acne, rosacea, eczema).
7.Subjects with history of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, medication, cosmetic or personal care products or ingredients.
8.Subject presenting a stable or progressive serious disease (per investigator's assessment).
9.Immuno-compromised subject. 10.Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
11.Subjects regularly practicing aquatic or nautical sports. 12.Subjects regularly attending a sauna. 13.Subject with cardiovascular or circulatory history. 14.Subject with a history of skin cancer or malignant melanoma. 15.Anti-aging medical beauty project or anti-aging cosmetics clinical research in the last 6 months before study.
16.Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.
20 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChinaNorm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C25005004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.